Add To My Watchlist

Green Zone Power Rating: 4 High-Risk

Action to take: AVOID or SHORT
High-Risk stocks are expected to significantly underperform the market over the next 12 months. Short positions may capitalize on potentially negative price returns.
Price Based
Fundamental Based
Negative Factors (Bottom 20%)
Momentum: Stocks in downtrends and with significantly lagging momentum should be avoided.
Size: Stocks of the largest companies tend to lag the returns of otherwise equally-rated smaller companies.
Volatility: Stocks of the highest volatility typically underperform and pose unduly higher risk.
Collapse Detail

Latest Insights on MRNA

Moderna stock MRNA stock An Investor’s Guide to Moderna Stock
by Money and Markets Staff January 18, 2023 Investing
COVID-19 introduced a race for a vaccine, but how does Moderna stock (Nasdaq: MRNA) rate now that the pandemic is in the rearview mirror?
Moderna stock MRNA stock “Bullish” Moderna’s Latest Moves: Stock Power Breakdown
by Fletcher Post October 28, 2022 Investing
Things aren't quite back to normal yet, but it looks a lot less bleak because of the vaccines. Especially for Moderna's stock.
dna storage stock Moderna MRNA A 1,700% Shot in the Arm: MRNA Put the Spotlight on Genomics
by Charles Sizemore May 26, 2022 Investing
Mega trends are imperative while in a bear market. Moderna helped genomics shoot to the top, see how this can help spot future trends.
stock market mega trend 2022 3 Market Mega Trends for 2022 and Beyond
by Adam O'Dell December 10, 2021 Investing
There are plenty of market mega trends to track in 2022. Here are three that chief investment strategist Adam O'Dell is most excited about.
genomics COVID trade COVID Trade Is Dead: Genomics Is Ready for the Spotlight
by Adam O'Dell November 12, 2021 Investing
COVID-19 may not be a reliable investing theme anymore, but it opened the door for the biggest stock mega trend of the next decade.